Guselkumab biosimilar(Samsung Bioepis Co Ltd)

N/A

Report date: 2026/02/09 20:01:27

Base Information

Drug NameGuselkumab biosimilar(Samsung Bioepis Co Ltd)
Drug Alias NameSB-34SB34
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-23 subunit p19 inhibitors
TargetsInterleukin-23 subunit p19
Therapy Area/IndicationsImmune System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSamsung Bioepis Co Ltd
Inactive CompaniesN/A
Active IndicationsImmune System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A